doi:10.3969/j.issn.1673-8640.2026.03.011

Abstract

CLC Number:

R373.9

Figures/Tables 6

References 17

[1]	CHOU S, ALAIN S, CERVERA C, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients[J]. J Infect Dis, 2024, 229(2):413-421. DOI URL
[2]	何瑞芬, 马雯, 梁爱玲, 等. HCMV-DNA定量检测和HCMV-IgG抗体AI检测在儿童HCMV感染诊断中的临床价值[J]. 现代生物医学进展, 2022, 22(4):737-740.
[3]	中华医学会围产医学分会, 中华医学会妇产科学分会产科学组, 《中华围产医学杂志》编辑委员会. 妊娠期巨细胞病毒感染筛查与处理专家共识[J]. 中华围产医学杂志, 2017, 20(8):553-556.
[4]	邱佩绵, 梁雪雁, 温瑛梦, 等. 妊娠早期巨细胞病毒感染和产前诊断案例分析[J]. 国际妇产科学杂志, 2022, 49(6):675-678.
[5]	Society for Maternal-Fetal Medicine(SMFM), HUGHES B L, GYAMFI-BANNERMAN C. Diagnosis and antenatal management of congenital cytomegalovirus infection[J]. Am J Obstet Gynecol,2016 Jun, 214(6):B5-B11. DOI URL
[6]	吴培豪, 周俞, 吴开奇, 等. 巨细胞病毒感染新生儿血清IgM抗体和病毒载量与临床症状的相关性研究[J]. 中华预防医学杂志, 2022, 56(11):1642-1647.
[7]	郭靖, 赵祖英. 血清游离人绒毛膜促性腺激素水平与宫内感染巨细胞病毒的相关性分析[J]. 中国妇幼保健, 2022, 37(2):217-219.
[8]	WU K, HOU Y J, MAKRINOS D, et al. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults[J]. J Virol, 2024, 98(4):160323.
[9]	强玉娜, 吕树志, 邢祝乔, 等. 巨细胞病毒感染与冠心病重症患者血液流变学和内毒素水平及预后的关系[J]. 中华医院感染学杂志, 2022, 32(23):3562-3566.
[10]	VIANA L A, CRISTELLI M P, BASSO G, et al. Conversion to mTOR inhibitor to reduce the incidence of cytomegalovirus recurrence in kidney transplant recipients receiving preemptive treatment:a prospective,randomized trial[J]. Transplantation, 2024, 108(4):63.
[11]	ZAMORA D, DASGUPTA S, STEVENS-AYERS T, et al. Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis[J]. JCI Insight, 2024, 9(18):180115.
[12]	刘鑫, 金米聪. 宁波地区5 497例人巨细胞病毒荧光定量PCR检测结果分析[J]. 中国卫生检验杂志, 2022, 32(19):2386-2388.
[13]	SINGH N, WINSTON D J, RAZONABLE R R, et al. Unexpected cytomegalovirus(CMV)replication kinetics in CMV donor-seropositive,recipient-seronegative liver transplant recipients receiving preemptive antiviral therapy[J]. J Infect Dis, 2022, 225(3):436-442. DOI URL
[14]	陈思敏, 刘鹏飞, 陆立东, 等. 婴儿巨细胞病毒感染性肝炎病毒载量与γ-GGT的相关性及其对预后预测价值[J]. 河北医科大学学报, 2022, 43(12):1454-1458.
[15]	PARENTE P, ASCANI S, MAIORANO B A, et al. Letter:be careful of gastrointestinal CMV infection in adverse events from ICIs therapy in solid tumours[J]. Aliment Pharmacol Ther, 2023, 57(8):916-917. DOI URL
[16]	李雪国, 王如民, 徐艳芳, 等. 新疆地区儿童异基因造血干细胞移植后巨细胞病毒感染相关危险因素分析[J]. 中国小儿血液与肿瘤杂志, 2023, 28(4):243-247.
[17]	罗芸, 陈晶, 夏乐莎, 等. 巨细胞病毒感染性流产IL^-1、TLR4、E-cadherin基因的表达及意义[J]. 中华医院感染学杂志, 2021, 31(7):1071-1075.

组别	例数	IgG抗体/（IU·mL^-1）	IgM抗体/COL	HCMV DNA/（拷贝·mL^-1）
感染组	315	18.43±5.91	1.92±2.03	474.69±154.52
未感染组	105	7.47±2.09	0.62±0.11	437.18±69.88
t值		18.582	6.555	2.405
P值		<0.001	<0.001	0.017

组别	例数	IgG抗体/（IU·mL^-1）	IgM抗体/COL	HCMV DNA/（拷贝·mL^-1）
感染组	315	18.43±5.91	1.92±2.03	474.69±154.52
未感染组	105	7.47±2.09	0.62±0.11	437.18±69.88
t值		18.582	6.555	2.405
P值		<0.001	<0.001	0.017

组别	例数	IgG抗体/ （IU·mL^-1）	IgM抗体/ COL	HCMV DNA/ （拷贝·mL^-1）
活动性感染组	89	21.92±9.72	5.00±1.12	700.56±108.63
既往感染组	226	17.06±2.29	0.71±0.16	385.74±24.05
t值		7.051	56.623	41.173
P值		<0.001	<0.001	<0.001

组别	例数	IgG抗体/ （IU·mL^-1）	IgM抗体/ COL	HCMV DNA/ （拷贝·mL^-1）
活动性感染组	89	21.92±9.72	5.00±1.12	700.56±108.63
既往感染组	226	17.06±2.29	0.71±0.16	385.74±24.05
t值		7.051	56.623	41.173
P值		<0.001	<0.001	<0.001

组别	例数	流产/[例（%）]	先天畸形/[例（%）]	新生儿窒息/[例（%）]	低出生体重/[例（%）]	合计/[例（%）]
活动性感染组	89	4（4.49）	1（1.12）	4（4.49）	6（6.74）	15（16.85）
既往感染组	226	6（2.65）	0（0）	3（1.33）	5（2.21）	14（6.19）^*
未感染组	105	4（3.81）	0（0）	1（0.95）	4（3.81）	9（8.57）^*
χ²值						8.885
P值						0.012

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 17

Related Articles 15

Recommended Articles

Metrics

项目	β值	标准误	Wald值	P值	OR^①值（95%CI^②）
IgG抗体	0.109	0.030	12.914	<0.001	1.115（1.051~1.184）
IgM抗体	0.700	0.248	7.983	0.005	2.014（1.239~3.274）
HCMV DNA	0.011	0.003	13.106	<0.001	1.011（1.005~1.017）

项目	AUC（95%CI）	最佳临界值	敏感性/%	特异性/%	约登指数
IgG抗体	0.630（0.514~0.746）	19.81 IU·mL^-1	42.10	93.20	0.353
IgM抗体	0.675（0.588~0.762）	0.625 COL	89.50	36.30	0.261
HCMV DNA	0.707（0.616~0.797）	717.41拷贝·mL^-1	39.50	95.30	0.348
3项联合检测	0.831（0.745~0.918）	125.10	68.40	96.90	0.635

[1]	ZHANG Chaomin, YANG Chihui, YI Changlin, LU Wenyuan. Human papillomavirus genotype analysis of different cervical lesion patients in Shanghai [J]. Laboratory Medicine, 2026, 41(2): 182-185.
[2]	WANG Jing, ZHANG Yifan, WANG Gang, LIN Feng, ZHANG Min, LI Xin, ZHANG Mingming, WAN Yanmin, ZHU Zhaoqin. Analysis of clinical and immunological characteristics of HIV-positive and HIV-negative monkeypox patients [J]. Laboratory Medicine, 2025, 40(12): 1139-1145.
[3]	WANG Chunwei, MA Xiuqing, QI Guochang, CAI Xingyao. Result analysis of nucleic acid testing in different specimen types for human cytomegalovirus [J]. Laboratory Medicine, 2025, 40(9): 881-884.
[4]	ZHU Jieke, ZHOU Peng, LUO Ying, WU Maofeng, XUAN Shuxia, CHEN Chen, QI Huaxin, OUYANG Yu, YIN Weiguo. Correlation of HPV combined with lower genital tract pathogen infection and cervical lesion [J]. Laboratory Medicine, 2024, 39(11): 1097-1100.
[5]	. [J]. Laboratory Medicine, 2024, 39(9): 908-912.
[6]	YAN Jianghong, WANG Le, MA Lin, YANG Shuo, GUO Weiwei, ZHAO Mengchuan, LIU Zehao, ZHAI Xiaoying. Clinical characteristics of acute lymphoblastic leukemia children infected with Epstein-Barr virus [J]. Laboratory Medicine, 2024, 39(6): 583-586.
[7]	WANG Xuqin, LIN Qianru, FENG Wanqing, DONG Yuan, YU Xiaolei, LIU Changhe, NING Zhen, SHEN Xin, PAN Qichao, LIN Yi. Validation of HIV-1 integrase genotyping sequence assay [J]. Laboratory Medicine, 2024, 39(4): 369-375.
[8]	. [J]. Laboratory Medicine, 2024, 39(1): 71-74.
[9]	LU Xinli, LIU Yong, LI Yan, WANG Yingying, AN Ning, LIU Meng. Identification of near full-length genome structures of new HIV-1 recombinant strains [J]. Laboratory Medicine, 2023, 38(11): 1015-1019.
[10]	ZHANG Yaxu, CUI Yanwei, LIU Ziyan. Preliminary research for the determination of HPV E6/E7 mRNA by nucleic acid molecular hybridization-flow cytometry [J]. Laboratory Medicine, 2023, 38(1): 46-50.
[11]	LIU Hongqian, SONG Chaohui, LIANG Qiaomi. Determination and quantitation of blood human papillomavirus DNA in healthy subjects [J]. Laboratory Medicine, 2021, 36(11): 1121-1124.
[12]	ZHANG Yunli, WANG Xin, SHAO Ling, QU Bo, ZHAO Hongmei. Comparison of different nucleic acid extraction methods for the detection of SARS-Cov-2 [J]. Laboratory Medicine, 2021, 36(5): 530-534.
[13]	XUAN Binbin, TAN Meiyu, SUN Hanxiao, SHENG Huiming. Mixed infection status of human papillomavirus,Ureaplasma urealyticum,Chlamydia trachomatis and Neisseria gonorrhoeae in Changning district of Shanghai [J]. Laboratory Medicine, 2020, 35(9): 859-863.
[14]	YAN Jianghong, JA Li, LI Wenhui, YANG Shuo, YAN Xiaotong, ZHAO Mengchuan, GUO Weiwei, LIU Yingye, LIU Zehao, WANG Le. Epidemiological characteristics of EB virus infection in inpatients from Hebei Children's Hospital [J]. Laboratory Medicine, 2020, 35(4): 323-326.
[15]	SHEN Qionghua. Role of HPV DNA typing in the differential diagnosis of cervical lesions and cervical cancer [J]. Laboratory Medicine, 2019, 34(6): 498-501.